| Date | Time | Source | Headline | Symbol | Company |
| 01/31/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 01/20/2023 | 4:03PM | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 01/06/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 01/03/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/23/2022 | 4:14PM | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/22/2022 | 10:35PM | TipRanks | SVB Securities Sticks to Its Hold Rating for Enanta Pharmaceuticals (ENTA) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/22/2022 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Participate in Two Investor Conferences in November | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/21/2022 | 4:02PM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/14/2022 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/13/2022 | 10:55PM | TipRanks | SVB Securities Sticks to Their Hold Rating for Enanta Pharmaceuticals (ENTA) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/09/2022 | 4:35PM | TipRanks | Enanta Pharmaceuticals (ENTA) Gets a Buy from JMP Securities | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/09/2022 | 7:00AM | Business Wire | Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/19/2022 | 8:00AM | Business Wire | Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/17/2022 | 7:00AM | Business Wire | Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/03/2022 | 7:00AM | Business Wire | Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/29/2022 | 7:00AM | Business Wire | Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/22/2022 | 7:01AM | Business Wire | Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/14/2022 | 12:25PM | TipRanks | JMP Securities Sticks to Its Buy Rating for Enanta Pharmaceuticals (ENTA) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/07/2022 | 8:30AM | Business Wire | New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/01/2022 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Participate in Two Investor Conferences in September | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/26/2022 | 4:08PM | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/11/2022 | 4:32PM | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/10/2022 | 11:16PM | TipRanks | SVB Securities Reaffirms Their Hold Rating on Enanta Pharmaceuticals (ENTA) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/09/2022 | 8:35AM | TipRanks | RBC Capital Sticks to Their Hold Rating for Enanta Pharmaceuticals (ENTA) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/08/2022 | 9:45PM | TipRanks | JMP Securities Keeps Their Buy Rating on Enanta Pharmaceuticals (ENTA) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/08/2022 | 4:05PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/08/2022 | 4:03PM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/08/2022 | 4:00PM | Business Wire | Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/01/2022 | 8:41AM | TipRanks | Enanta Pharmaceuticals (ENTA) Receives a Hold from SVB Securities | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/01/2022 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |